The abstract is read at the publisher; the summary is JClub's.
In the ENCIRCLE MAC Registry, transseptal TMVR with the SAPIEN M3 system achieved MR ≤1+ in 98.5% of implanted patients at 1 year for symptomatic MAC-related MVD.
- Why it matters: Patients with symptomatic mitral valve dysfunction linked to mitral annular calcification often cannot undergo surgery or transcatheter repair, leaving uncertain benefits from a fully percutaneous transseptal replacement approach.
- What they did: This prospective, multicenter, single-arm study enrolled 364 screened patients with MAC-related MVD unsuitable for surgery or transcatheter repair; TVMR was attempted in 100 and implanted in 93 using the SAPIEN M3 system via transseptal access.
- The result: At 1 year, Kaplan-Meier all-cause mortality or heart failure hospitalization was 33.6% (95% CI: 25.0%–44.1%), while disabling stroke was 5.1% and MR reduction with symptom and quality-of-life improvements persisted through 1 year.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.